Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
GEVA's Cash to Debt is ranked higher than
84% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. GEVA: No Debt )
GEVA' s 10-Year Cash to Debt Range
Min: 0.63   Max: 58941
Current: No Debt

0.63
58941
Equity to Asset 0.95
GEVA's Equity to Asset is ranked higher than
97% of the 772 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. GEVA: 0.95 )
GEVA' s 10-Year Equity to Asset Range
Min: -4.72   Max: 0.98
Current: 0.95

-4.72
0.98
Interest Coverage No Debt
GEVA's Interest Coverage is ranked higher than
87% of the 447 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GEVA: No Debt )
GEVA' s 10-Year Interest Coverage Range
Min: 7.93   Max: 9999.99
Current: No Debt

7.93
9999.99
F-Score: 2
Z-Score: 46.40
M-Score: -3.52
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -1663.58
GEVA's Operating margin (%) is ranked higher than
54% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: -55.17 vs. GEVA: -1663.58 )
GEVA' s 10-Year Operating margin (%) Range
Min: -6866.73   Max: 120.8
Current: -1663.58

-6866.73
120.8
Net-margin (%) -1658.95
GEVA's Net-margin (%) is ranked higher than
54% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: -51.98 vs. GEVA: -1658.95 )
GEVA' s 10-Year Net-margin (%) Range
Min: -7000   Max: 81
Current: -1658.95

-7000
81
ROE (%) -30.84
GEVA's ROE (%) is ranked higher than
71% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -25.77 vs. GEVA: -30.84 )
GEVA' s 10-Year ROE (%) Range
Min: -105.21   Max: 52.19
Current: -30.84

-105.21
52.19
ROA (%) -29.57
GEVA's ROA (%) is ranked higher than
69% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -19.98 vs. GEVA: -29.57 )
GEVA' s 10-Year ROA (%) Range
Min: -74.33   Max: 32.45
Current: -29.57

-74.33
32.45
ROC (Joel Greenblatt) (%) -729.19
GEVA's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -210.62 vs. GEVA: -729.19 )
GEVA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2491.51   Max: 320.19
Current: -729.19

-2491.51
320.19
Revenue Growth (%) -70.40
GEVA's Revenue Growth (%) is ranked higher than
56% of the 653 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. GEVA: -70.40 )
GEVA' s 10-Year Revenue Growth (%) Range
Min: -70.4   Max: 158
Current: -70.4

-70.4
158
EBITDA Growth (%) -79.90
GEVA's EBITDA Growth (%) is ranked higher than
52% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. GEVA: -79.90 )
GEVA' s 10-Year EBITDA Growth (%) Range
Min: -79.9   Max: 30.9
Current: -79.9

-79.9
30.9
EPS Growth (%) -78.50
GEVA's EPS Growth (%) is ranked higher than
53% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. GEVA: -78.50 )
GEVA' s 10-Year EPS Growth (%) Range
Min: -78.5   Max: 30.5
Current: -78.5

-78.5
30.5
» GEVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

GEVA Guru Trades in Q3 2013

George Soros 17,700 sh (New)
Columbia Wanger 3,224,000 sh (+29.72%)
Jim Simons Sold Out
Steven Cohen 3,187 sh (-93.52%)
» More
Q4 2013

GEVA Guru Trades in Q4 2013

Steven Cohen Sold Out
George Soros Sold Out
Columbia Wanger 3,217,000 sh (-0.22%)
» More
Q1 2014

GEVA Guru Trades in Q1 2014

Columbia Wanger 3,093,000 sh (-3.85%)
» More
Q2 2014

GEVA Guru Trades in Q2 2014

Columbia Wanger 3,521,000 sh (+13.84%)
» More
» Details

Insider Trades

Latest Guru Trades with GEVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2013-12-31 Sold Out 0.01%$45.51 - $69.69 $ 76.9730%0
George Soros 2013-09-30 New Buy0.01%$43.26 - $62.55 $ 76.9757%17700
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.53
GEVA's P/B is ranked higher than
70% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. GEVA: 4.53 )
GEVA' s 10-Year P/B Range
Min: 0.76   Max: 17.16
Current: 4.53

0.76
17.16
P/S 274.89
GEVA's P/S is ranked higher than
51% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.61 vs. GEVA: 274.89 )
GEVA' s 10-Year P/S Range
Min: 1.04   Max: 370.64
Current: 274.89

1.04
370.64
EV-to-EBIT -13.83
GEVA's EV-to-EBIT is ranked higher than
51% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GEVA: -13.83 )
GEVA' s 10-Year EV-to-EBIT Range
Min: -153.9   Max: 40.5
Current: -13.83

-153.9
40.5
Current Ratio 20.01
GEVA's Current Ratio is ranked higher than
96% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. GEVA: 20.01 )
GEVA' s 10-Year Current Ratio Range
Min: 3.17   Max: 54.89
Current: 20.01

3.17
54.89
Quick Ratio 20.01
GEVA's Quick Ratio is ranked higher than
96% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. GEVA: 20.01 )
GEVA' s 10-Year Quick Ratio Range
Min: 3.17   Max: 54.89
Current: 20.01

3.17
54.89

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.07
GEVA's Price/Net Cash is ranked higher than
92% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 125.18 vs. GEVA: 5.07 )
GEVA' s 10-Year Price/Net Cash Range
Min: 1.09   Max: 220.96
Current: 5.07

1.09
220.96
Price/Net Current Asset Value 5.05
GEVA's Price/Net Current Asset Value is ranked higher than
91% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 57.00 vs. GEVA: 5.05 )
GEVA' s 10-Year Price/Net Current Asset Value Range
Min: 1.06   Max: 170.45
Current: 5.05

1.06
170.45
Price/Tangible Book 4.63
GEVA's Price/Tangible Book is ranked higher than
82% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 8.79 vs. GEVA: 4.63 )
GEVA' s 10-Year Price/Tangible Book Range
Min: 1.01   Max: 19.37
Current: 4.63

1.01
19.37
Price/DCF (Projected) 22.24
GEVA's Price/DCF (Projected) is ranked higher than
90% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GEVA: 22.24 )
GEVA' s 10-Year Price/DCF (Projected) Range
Min: 0.01   Max: 29.99
Current: 22.24

0.01
29.99
Price/Median PS Value 17.94
GEVA's Price/Median PS Value is ranked higher than
66% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. GEVA: 17.94 )
GEVA' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 58
Current: 17.94

0.1
58
Earnings Yield (Greenblatt) -7.20
GEVA's Earnings Yield (Greenblatt) is ranked lower than
187% of the 312 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. GEVA: -7.20 )
GEVA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.5   Max: 3528.7
Current: -7.2

2.5
3528.7
Forward Rate of Return (Yacktman) -40.45
GEVA's Forward Rate of Return (Yacktman) is ranked higher than
64% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: -9.72 vs. GEVA: -40.45 )
GEVA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -99.6   Max: 26.1
Current: -40.45

-99.6
26.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:TMS1.Germany
Synageva BioPharma Corp is incorporated in Delaware in 1993. It is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients with life-threatening rare diseases and unmet medical needs. The Company has several proteins therapeutic in its pipeline, including two enzyme replacement therapies for lysosomal storage disorders and two additional programs for other life-threatening genetic conditions for which there are currently no approved treatments. Its program, sebelipase alfa, is a recombinant human lysosomal acid lipase ("LAL") currently under clinical investigation in North America and the European Union ("EU") for the treatment of patients with early onset and late onset LAL Deficiency, which is a rare, devastating disease that causes significant morbidity and mortality. Synageva currently evaluates sebelipase alfa in global clinical trials and sebelipase alfa has been granted orphan designations by the U.S. Food and Drug Administration ("FDA"), the European Medicines Agency, and the Japanese Ministry of Health, Labour and Welfare. Additionally, sebelipase alfa has received Fast Track Designation by the FDA. Synageva has not yet received approval to market this product and is not currently commercializing any other products. It has assembled a team with a proven record of bringing orphan therapies to patients. It has retained the rights to its pipeline programs, including program, sebelipase alfa (formerly referred to as SBC-102) for the treatment of ultra-rare LSD known as lysosomal acid lipase deficiency (LAL Deficiency). Sebelipase alfa is a recombinant form of the human LAL enzyme under development as an enzyme replacement therapy for LAL Deficiency. The Company is currently enrolling and dosing infants with early onset LAL Deficiency in a Phase II/III open-label trial with sebelipase alfa. Its potential competitors include large pharmaceutical and biotechnology companies and specialty pharmaceutical companies, academic institutions, government agencies, and research institutions. The preclinical studies and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its product candidates and future products, are subject to extensive regulation by governmental authorities in the U.S. and other countries.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK